BioMarin Pharmaceutical (BMRN) Proxy filing summary

Executive summary

• Annual Meeting scheduled for June 2, 2026, with voting on four key proposals, including director elections, auditor ratification, executive compensation, and an amendment to the equity incentive plan.

• Company reported $3.2 billion in 2025 revenue, up 13% from 2024, with strong growth in VOXZOGO and successful acquisitions of Inozyme Pharma and a pending acquisition of Amicus Therapeutics.

• Board leadership transition: Ian Clark to succeed Richard A. Meier as Chair following the meeting.

• Strategic focus on innovation, pipeline expansion, and global reach, with continued emphasis on rare disease therapies.

Voting matters and shareholder proposals

• Election of ten directors to serve until the next annual meeting.

• Ratification of KPMG LLP as independent auditor for fiscal year ending December 31, 2026.

• Advisory vote on executive compensation (say-on-pay).

• Approval of an amendment to the 2017 Equity Incentive Plan to increase shares reserved for issuance by 7,650,000.

• Board recommends voting FOR all proposals.

Board of directors and corporate governance

• Board refreshment: six of ten nominees new since 2022; average tenure reduced to 4.0 years.

• Nine of ten directors are independent; diverse board with 50% total diversity and broad expertise in R&D, finance, and governance.

• Majority voting standard adopted for uncontested director elections.

• Regular board and committee self-evaluations, succession planning, and director education.

• Separation of Chair and CEO roles since December 2023.